Mitsubishi Chemical Holdings unit Life Science Institute has bought multilineage-differentiating stress-enduring (Muse) stem cell firm Clio for more than 1 billion yen ($8 million), according to a press release. Life Sciences in a Japanese language release on May 14 said Clio will become a wholly-owned subsidiary.
South Korea's Green Cross Holdings and POSCO Capital joined to buy a $7.5 million stake in U.S.-based Juventas Therapeutics, pushing a regenerative and biologics growth strategy that has seen recent deals in China and Russia.
The new president of Japan's Riken research institute vowed to enter into partnerships with more businesses as part of his plan for reform of the institution hit by a scandal over its stem cell research.
China health authorities have proposed some new regulations for conducting stem-cell clinical trials in the country, one requiring that a 30-year archive of the clinical records of stem-cell donors and patients be maintained.
Scientists at the Scripps Research Institute say they've identified an enzyme necessary for maintaining the stability of hematopoietic stem cells.
Researchers in Japan said they have been able to stop the deterioration associated with muscular dystrophy by creating stem cells and implanting them in a mouse.
A group of bioengineers at UC Berkeley has been hard at work hatching a new "heart-on-a-chip" technology that aims to offer researchers a better, less expensive way to develop new drugs.
Investigators say that they've identified a pathway that can be used to target brain tumor stem cells, adding to potential therapeutic strategies for the aggressive disease glioblastoma.
Scientists say that they have developed a method to use modified messenger RNA to lengthen telomeres, opening a pathway to countering the effects of aging in cells--a process that might apply to a range of diseases from DMD to diabetes and heart disease.
Pancreatic cancer has long loomed as one of the most aggressive killers, typically leaving patients with a poor prognosis and specialists with few options for effective treatment. But now a team at the University of Michigan in Ann Arbor says they have new reason to believe that a particular gene is responsible for the fast-spreading cancer--offering a clear target for drug developers.